Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Rheumatoid Arthritis
Phase II Efficacy Study Enrollment of C5 Complement Inhibitor Completed
September 9th, 2000
Alexion Pharmaceuticals, Inc. (ALXN), New Haven, Connecticut, announced that it has completed patient enrollment with 5G1.1, its anti-inflammatory complement inhibitor drug candidate, in a Phase II efficacy trial in rheumatoid arthritis patients. 5G1.1 is a fully humanized monoclonal antibody that has been shown to potently block the inflammatory effects of the complement system. The Phase II multi-center, double-blinded, randomized, placebo-controlled study is designed to examine the safety and clinical efficacy of repeated dosing of 5G1.1 during a three-month period in approximately 200 rheumatoid arthritis patients in the United States. This...
Source: Pain & Central Nervous System Week (2000-09-09)
|
